Aetna · Gene Therapy Lyfgenia · US health-plan appeal rights

Gene Therapy Lyfgenia denied for failing step therapy by Aetna?

Q: How long do I have to appeal a Aetna Gene Therapy Lyfgenia denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Aetna typically requires

Aetna's specific coverage criteria for gene therapy lyfgenia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Aetna Clinical Policy Bulletin / 0996 — Gene Therapy and HSCT for Hemoglobinopathies

The Aetna angle on Gene Therapy Lyfgenia

## Why Aetna Issues Step-Therapy Denials for Lyfgenia

Step-therapy (or "fail-first") denials require a patient to try and fail one or more lower-cost treatments before the plan will cover the requested therapy. For Lyfgenia, this type of denial is particularly significant because sickle cell disease patients are typically adults or adolescents who have already lived with the disease for years, often with an extensive treatment history. Aetna may nonetheless issue an automated step-therapy denial if the submitted prior-authorization request does not explicitly document that history.

## Why This Denial Is Appealable

Step-therapy protocols must yield when a patient has already tried and failed — or has a documented clinical contraindication to — the required prior therapies. Most states also have step-therapy exception laws that require insurers to grant an exception when prior therapy has been tried and was inadequate, caused harm, or is clinically contraindicated. If the patient's chart demonstrates years of disease management with other agents, the step-therapy requirement is already satisfied on the facts.

## Your Appeal Rights and Timeline

Internal appeal: File within the deadline on your denial letter. Aetna must decide pre-service appeals within 30 days and post-service claims within 60 days.
Step-therapy exception: Simultaneously, submit a formal step-therapy exception request supported by the prescriber's letter. Many states mandate a decision within 72 hours for urgent cases.
External review (ACA §2719): A final internal denial triggers the right to independent external review, generally within 4 months of that final denial. The IRO applies clinical standards — not insurer policy — to evaluate whether the step requirement was appropriate.
ERISA §503: Employer-plan members are entitled to full-and-fair review and access to all plan documents used in the denial decision.

## Documentation to Gather

1. Diagnosis confirmation: Records establishing the sickle cell disease diagnosis and the specific disease genotype. 2. Prior-treatment history: A chronological list of all prior disease-modifying therapies with start/stop dates, doses (from the chart), and documented outcomes — including hospitalizations, pain crises, and organ complications that occurred despite treatment. 3. Clinical severity documentation: Recent chart notes, lab trends, and any imaging or organ-function studies that illustrate ongoing disease burden. 4. Prescriber medical-necessity letter: The hematologist's narrative explaining why Lyfgenia is medically necessary now and why continued step-therapy with prior agents is inadequate or poses unacceptable risk — citing the patient's specific clinical course, not generic statistics. 5. Step-therapy exception criteria: Compare the plan's exception criteria against the documented history and note each criterion that is satisfied.

## Criteria-Mapping Structure

Obtain Aetna's current published coverage policy for Lyfgenia and list each step-therapy requirement. For each one, cite the specific chart evidence:

| Step-Therapy Requirement | Patient-Specific Evidence | |---|---| | Prior therapy tried | [Agent, dates, prescriber, chart note reference] | | Inadequate response documented | [Hospitalizations, crisis frequency, lab trends] | | Clinical exception criteria met | [Prescriber letter section, chart note date] | | FDA-approved indication confirmed | [Diagnosis + genotype lab report] |

A structured letter that maps each requirement to a specific chart fact is substantially more persuasive than a narrative-only appeal.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Aetna appeals

Other insurers on Gene Therapy Lyfgenia

State Medicaid (varies) denied for failing step therapy of Gene Therapy Lyfgenia

Other denial reasons for Aetna Gene Therapy Lyfgenia

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.